WallStreetZenWallStreetZen

NASDAQ: BCYC
Bicycle Therapeutics PLC Stock

$23.45-1.04 (-4.25%)
Updated Apr 19, 2024
BCYC Price
$23.45
Fair Value Price
-$23.18
Market Cap
$998.65M
52 Week Low
$12.54
52 Week High
$28.91
P/E
-4.62x
P/B
2.69x
P/S
23.86x
PEG
N/A
Dividend Yield
N/A
Revenue
$26.98M
Earnings
-$180.66M
Gross Margin
100%
Operating Margin
-652.22%
Profit Margin
-669.7%
Debt to Equity
0.61
Operating Cash Flow
-$61M
Beta
0.83
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A

BCYC Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BCYC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BCYC ($23.45) is overvalued by 201.17% relative to our estimate of its Fair Value price of -$23.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BCYC ($23.45) is not significantly undervalued (201.17%) relative to our estimate of its Fair Value price of -$23.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BCYC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BCYC due diligence checks available for Premium users.

Be the first to know about important BCYC news, forecast changes, insider trades & much more!

BCYC News

Valuation

BCYC fair value

Fair Value of BCYC stock based on Discounted Cash Flow (DCF)
Price
$23.45
Fair Value
-$23.18
Undervalued by
201.17%
BCYC ($23.45) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BCYC ($23.45) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BCYC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BCYC price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.62x
Industry
15.81x
Market
40.51x

BCYC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.69x
Industry
5.74x
BCYC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BCYC's financial health

Profit margin

Revenue
$5.3M
Net Income
-$49.1M
Profit Margin
-921%
BCYC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BCYC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$595.3M
Liabilities
$224.4M
Debt to equity
0.61
BCYC's short-term assets ($561.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BCYC's short-term assets ($561.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BCYC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BCYC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$47.3M
Investing
-$51.0k
Financing
$386.0k
BCYC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BCYC vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BCYC$998.65M-4.25%-4.62x2.69x
PHVS$1.00B+4.02%-6.78x2.43x
LQDA$1.01B-3.77%-10.98x21.36x
MGNX$974.56M-2.86%-104.07x6.39x
BLTE$974.47M-3.38%-28.09x10.78x

Bicycle Therapeutics Stock FAQ

What is Bicycle Therapeutics's quote symbol?

(NASDAQ: BCYC) Bicycle Therapeutics trades on the NASDAQ under the ticker symbol BCYC. Bicycle Therapeutics stock quotes can also be displayed as NASDAQ: BCYC.

If you're new to stock investing, here's how to buy Bicycle Therapeutics stock.

What is the 52 week high and low for Bicycle Therapeutics (NASDAQ: BCYC)?

(NASDAQ: BCYC) Bicycle Therapeutics's 52-week high was $28.91, and its 52-week low was $12.54. It is currently -18.89% from its 52-week high and 87% from its 52-week low.

How much is Bicycle Therapeutics stock worth today?

(NASDAQ: BCYC) Bicycle Therapeutics currently has 42,586,185 outstanding shares. With Bicycle Therapeutics stock trading at $23.45 per share, the total value of Bicycle Therapeutics stock (market capitalization) is $998.65M.

Bicycle Therapeutics stock was originally listed at a price of $12.00 in May 23, 2019. If you had invested in Bicycle Therapeutics stock at $12.00, your return over the last 4 years would have been 95.42%, for an annualized return of 18.23% (not including any dividends or dividend reinvestments).

How much is Bicycle Therapeutics's stock price per share?

(NASDAQ: BCYC) Bicycle Therapeutics stock price per share is $23.45 today (as of Apr 19, 2024).

What is Bicycle Therapeutics's Market Cap?

(NASDAQ: BCYC) Bicycle Therapeutics's market cap is $998.65M, as of Apr 20, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Bicycle Therapeutics's market cap is calculated by multiplying BCYC's current stock price of $23.45 by BCYC's total outstanding shares of 42,586,185.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.